Blue Owl Capital Holdings’s enGene Therapeutics ENGN Stock Holding History

Blue Owl Capital Holdings’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.1M	Buy	4,416,353 +1,055,416	+31%	+$9.4M	8.08%	3
2025 Q4	$30.3M	Buy	3,360,937 +82,831	+3%	+$664K	9.37%	1
2025 Q3	$22.4M	Sell	3,278,106 -450,000	-12%	-$2.05M	6.95%	3
2025 Q2	$13.6M	Buy	3,728,106 +448,728	+14%	+$1.68M	4.38%	7
2025 Q1	$14.7M	Buy	3,279,378 +119,403	+4%	+$742K	4.74%	7
2024 Q4	$21M	Buy	3,159,975 +101,006	+3%	+$784K	4.84%	8
2024 Q3	$20.2M	Buy	3,058,969 +609,142	+25%	+$4.53M	3.89%	9
2024 Q2	$23.1M	Sell	2,449,827 -11,523	-0.5%	-$148K	6.43%	6
2024 Q1	$41.7M	Buy	2,461,350 +1,226,590	+99%	+$15M	8.33%	4
2023 Q4	$11.4M	Buy	+1,234,760	New	+$10.9M	2.72%	12

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Blue Owl Capital Holdings's ENGN Position: Q1 2026 in Review

Blue Owl Capital Holdings increased its enGene Therapeutics (ENGN) stake by 31% in Q1 2026, buying an estimated $9.4M and bringing the position to 4,416,353 shares worth $30.1M. The position accounts for 8.08% of the portfolio, ranked #3.

Blue Owl Capital Holdings first reported a position in ENGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $41.7M in Q1 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Blue Owl Capital Holdings held 4,416,353 shares of enGene Therapeutics worth $30.1M as of Q1 2026.
Blue Owl Capital Holdings bought 1,055,416 enGene Therapeutics shares in Q1 2026, an estimated $9.4M.
enGene Therapeutics made up 8.08% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #3 holding.
Blue Owl Capital Holdings first reported a position in enGene Therapeutics in Q4 2023 and has held it in 10 quarters since.
Blue Owl Capital Holdings's enGene Therapeutics position peaked at $41.7M in Q1 2024.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.